Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncologists who Treat RCC (US)

Articles with lock require a subscription to GLG News | Request a free trial
July 11, 2007
Velcade superior to VAD induction to transplant
Analysis of: VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival | www.pipelinereview.com
Author: GLG Expert Contributor
no doubt that Velcade has shown superior results . it deserved to be used as induciton regimen ( unles patient has pre-existing neuropathy)  for transplant. velcade is  more efficacious ,less toxic and more easier to give than VAD regimen.
June 6, 2007
Is Wyeth's Torisel Better Than Wyeth's Rapamune?
Analysis of: FDA Approves Wyeth's Torisel For Treatment Of Advanced Kidney Cancer | www.medicalnewstoday.com
Author: GLG Expert Contributor
Torisel is a prodrug of Rapamune, Wyeth's marketed immunosuppressant product.  It is possible that cost concerns could lead to use of Rapamune as a "poor man's substitute" for Torisel.
March 16, 2007
Will Satraplatin Get Approved?
Analysis of: Satraplatin Shown to Significantly Reduce Risk of Disease Progression in Advanced Hormone-Refractory Prostate Cancer Patients | www.drugnewswire.com
Author: GLG Expert Contributor
The Satraplatin trial used an unusual endpoint, and the results may not be as good as they appear at first glance.
February 28, 2007
No surprise!
Analysis of: Threshold Pharmaceuticals Announces That a Phase 3 Clinical Trial of Glufosfamide for Treatment of Pancreatic Cancer Did Not Meet Its Primary Endpoint | pharmalive.com
Author: GLG Expert Contributor
This is another example where a phase III trial was conducted despite minimal evidence of efficacy in phase II.
November 27, 2006
The favorite drug
Analysis of: FDA Expands Use of Herceptin for Early Stage Breast Cancer After Primary Therapy | www.ptcommunity.com
Author: GLG Expert Contributor
1. Herceptin is one of the favorite drugs used by oncologists2. Optimal schedule and length is not clear3. Role of additional testing is not established4. Competition is around the corner
November 20, 2006
The drug is innocent, the management sucks
Analysis of: Cell Therapeutics: Xyotax faces more developmental delays | www.pharmaceutical-business-review.com
Author: GLG Expert Contributor
Implications: 1. Drug will be delayed further2. Abraxane and Epothilone B will be approved. 3. If management understood that approach of early 80s does not work now, the drug would be available on market years ago.  
November 20, 2006
Effectiveness vs cost –effectiveness
Analysis of: NICE rejects use of cancer drug Tarceva | www.pharmaceutical-business-review.com
Author: GLG Expert Contributor
1. The first working drug will not be approved because it is too expensive.2. Narrow indication: never smoker, EGFR (+) would likely be approved if submitted, but that would establish the precedent and affect many other drugs3. US regulatory authorities may follow suite.

Previous Page : 1 211 to 17 of 17

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617